Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AZD3152,Cilgavimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AZD5156 is an investigational, long-acting antibody combination of cilgavimab, a component of EVUSHELD (tixagevimab and cilgavimab, formerly AZD7442), and a new long-acting monoclonal antibody (mAb), AZD3152.
Product Name : AZD5156
Product Type : Antibody
Upfront Cash : Inapplicable
December 21, 2022
Lead Product(s) : AZD3152,Cilgavimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable